Injectable Biomaterials for Treatment of Glioblastoma
Authors:
- 30 August 2020
- journal article
- review article
- Published by Wiley in Advanced Materials Interfaces
- Vol. 7 (20)
Abstract
Despite ongoing advancements in the field of medicine, glioblastoma multiforme (GBM) is presently incurable, making this advanced brain tumor the deadliest tumor type in the central nervous system. The primary treatment strategies for GBM (i.e., surgical resection, radiation therapy, chemotherapy, and newly incorporated targeted therapies) fail to overcome the challenging characteristics of highly aggressive GBM tumors and are presently given with the goal of increasing the quality of life for patients. With the aim of creating effective treatment solutions, research has shifted toward utilizing injectable biomaterial adjuncts to minimize invasiveness of treatment, provide spatiotemporal control of therapeutic delivery, and engage with cells through material‐cell interfaces. This review aims to summarize the limitations of the current standard of care for GBM, discuss how these limitations can be addressed by local employment of injectable biomaterial systems, and highlight developments in the field of biomaterials for these applications.Keywords
Funding Information
- National Institutes of Health (R01NS112940)
This publication has 127 references indexed in Scilit:
- Rhenium-186 liposomes as convection-enhanced nanoparticle brachytherapy for treatment of glioblastomaNeuro-Oncology, 2012
- Shear-thinning hydrogels for biomedical applicationsSoft Matter, 2011
- Clinical significance of vasculogenic mimicry in human gliomasJournal of Neuro-Oncology, 2011
- Prolonged survival for patients with newly diagnosed, inoperable glioblastoma with 3-times daily ultrafractionated radiation therapyNeuro-Oncology, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- The Mechanical Rigidity of the Extracellular Matrix Regulates the Structure, Motility, and Proliferation of Glioma CellsCancer Research, 2009
- Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseNature, 2006
- Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapyBiochemical and Biophysical Research Communications, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A METHOD OF PERFORMING ABDOMINO-PERINEAL EXCISION FOR CARCINOMA OF THE RECTUM AND OF THE TERMINAL PORTION OF THE PELVIC COLON.The Lancet, 1908